QuiFLAPon 是一种选择性和特异性的FLAP抑制剂,可诱导细胞凋亡。它也是口服白三烯生物合成抑制剂,在完整的人和诱导的大鼠多形核白细胞 PMNLs 中,其IC50值分别为 3.1 nM 和 6.1 nM。
产品描述
Quiflapon causes cell apoptosis. Quiflapon is a selective and specific 5-lipoxygenase-activating protein (FLAP) inhibitor (IC50: 1.6 nM in a FLAP binding assay) and is also an effective and orally active Leukotriene biosynthesis (LT) inhibitor (IC50: 3.1 and 6.1 nM in intact human and elicited rat PMNLs, respectively).
体外活性
Quiflapon is an effective inhibitor of leukotriene (LT) biosynthesis in the human, squirrel monkey, and rat whole blood (IC50: 510, 69, and 9 nM, respectively). Quiflapon has a high affinity for 5-lipoxygenase activating protein (FLAP) as evidenced by an IC50 value of 1.6 nM in a FLAP binding assay and inhibition of the photoaffinity labeling of FLAP by two different photoaffinity ligands. However, Quiflapon has no effect on rat 5-lipoxygenase. The inhibition of activation of 5-lipoxygenase was shown through inhibition of the translocation of the enzyme from the cytosol to the membrane in human PMNLs[1].
体内活性
Pups were treated with either vehicle or Quiflapon(10, 20, or 40 mg/kg; daily for days 1-4, 5-9, or 10-14) subcutaneously. On day 14, the lungs were inflated, fixed, and stained for histopathological and morphometric analyses. Inhibition of antigen-induced bronchoconstriction by Quiflapon is observed in inbred rats pretreated with methysergide, Ascaris-challenged squirrel monkeys, and Ascaris-challenged sheep (early and late phase response) [1]. Hyperoxia groups treated with Quiflapon untreated hyperoxia groups displayed definite evidence of aberrant alveolarization but no inflammation[2].
Cas No.
136668-42-3
分子式
C34H35ClN2O3S
分子量
587.17
别名
MK-591;喹夫拉朋
储存和溶解度
H2O:< 0.1 mg/mL (insoluble)
DMSO:≥ 50 mg/mL (85.15 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years